Comparison between Bafna Pharmaceuticals IPO and MCX IPO.
Bafna Pharmaceuticals IPO is a Mainboard Bookbuilding IPO proposed to list at BSE while MCX IPO is a Mainboard Bookbuilding proposed to list at BSE.
The total issue size of Bafna Pharmaceuticals IPO is up to ₹25.60 Cr whereas the issue size of the MCX IPO is up to ₹663.31 Cr. The final issue price of Bafna Pharmaceuticals IPO is ₹40.00 per share and of MCX IPO is ₹1,032.00 per share.
| Bafna Pharmaceuticals IPO | MCX IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹860.00 per share | |
| Issue Price (Upper) | ₹1,032.00 per share | |
| Issue Price (Final) | ₹40.00 per share | ₹1,032.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹0.00 per share | |
| Market Lot Size | 6 shares | |
| Fresh Issue Size | 64,00,206 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹25.60 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 64,27,378 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹663.31 Cr |
| Issue Size Total | 64,00,206 shares | 64,27,378 shares |
| Issue Size Total (Amount) | up to ₹25.60 Cr | up to ₹663.31 Cr |
Bafna Pharmaceuticals IPO opens on May 27, 2008, while MCX IPO opens on Feb 22, 2012. The closing date of Bafna Pharmaceuticals IPO and MCX IPO is May 30, 2008, and Feb 24, 2012, respectively.
| Bafna Pharmaceuticals IPO | MCX IPO | |
|---|---|---|
| Anchor Bid Date | Feb 21, 2012 | |
| Issue Open | May 27, 2008 | Feb 22, 2012 |
| Issue Close | May 30, 2008 | Feb 24, 2012 |
| Basis Of Allotment (Tentative) | ||
| Initiation of Refunds (Tentative) | ||
| Credit of Share (Tentative) | ||
| Listing date (Tentative) | Jun 27, 2008 | Mar 09, 2012 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Bafna Pharmaceuticals IPO P/E ratio is , as compared to MCX IPO P/E ratio of .
| Bafna Pharmaceuticals IPO | MCX IPO | |||||
|---|---|---|---|---|---|---|
| Financials | Company Financials ()
| Company Financials ()
| ||||
| Promoter Shareholding (Pre-Issue) | 71.07 | 100 | ||||
| Promoter Shareholding (Post-Issue) | 42.6 | 26 | ||||
| P/E Ratio | ||||||
| Market Cap | ₹63.92 Cr. | ₹5263.03 Cr. | ||||
| ROE | ||||||
| ROCE | ||||||
| Debt/Equity | ||||||
| EPS | ||||||
| RoNW | 10.65 | 20.77 |
In the Bafna Pharmaceuticals IPO Retail Individual Investors (RII) are offered 32,00,000 shares while in MCX IPO retail investors are offered 32,00,000 shares. Qualified Institutional Buyers (QIB) are offered in Bafna Pharmaceuticals IPO and 21,62,083 shares in MCX IPO.
| Bafna Pharmaceuticals IPO | MCX IPO | |
|---|---|---|
| Anchor Investor Reservation | 9,26,606 shares | |
| Market Maker Reservation | ||
| QIB | 21,62,083 shares | |
| NII | 32,00,000 shares | 9,26,607 shares |
| RII | 32,00,000 shares | 21,62,082 shares |
| Employee | 2,50,000 shares | |
| Others | ||
| Total | 64,00,000 shares | 64,27,378 shares |
Bafna Pharmaceuticals IPO subscribed 4.88x in total, whereas MCX IPO subscribed 46.33x.
| Bafna Pharmaceuticals IPO | MCX IPO | |
|---|---|---|
| QIB (times) | 49.12x | |
| NII (times) | 1.57x | 150.35x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 8.20x | 24.14x |
| Employee (times) | 0.18x | |
| Other (times) | ||
| Total (times) | 4.88x | 46.33x |
